The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.
Alcoholic Liver Disease
Abstract
This guideline has been approved by the American Association for the Study of Liver Diseases (AASLD) and the American College of Gastroenterology and represents the position of both associations. These recommendations provide a data-supported approach. They are based on the following: (1) formal review and analysis of the recently published world literature on the topic (Medline search); (2) American College of Physicians Manual for Assessing Health Practices and Designing Practice Guidelines1; (3) guideline policies, including the AASLD Policy on the development and use of Practice Guidelines and the American Gastroenterological Association Policy Statement on Guidelines2; and (4) the experience of the authors in the specified topic. Intended for use by physicians, these recommendations suggest preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. They are intended to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case. Specific recommendations are based on relevant published information. To more fully characterize the quality of evidence supporting recommendations, the Practice Guideline Committee of the AASLD requires a Class (reflecting benefit versus risk) and Level (assessing strength or certainty) of Evidence to be assigned and reported with each recommendation (Table 1, adapted from the American College of Cardiology and the American Heart Association Practice Guidelines).3, 4 AASLD, American Association for the Study of Liver Diseases; AH, alcoholic hepatitis; ALD, alcoholic liver disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUDIT, Alcohol Use Disorders Identification Test; GAHS, Glasgow Alcoholic Hepatitis Score; GGT, gamma glutamyl transpeptidase; MDF, Maddrey discriminant function; MELD, Model for End-Stage Liver Disease; MRI, magnetic resonance imaging; PTU, propylthiouracil; SAMe, S-adenosyl L-methionine; TNF, tumor necrosis factor. Alcoholic liver disease (ALD) encompasses a spectrum of injury, ranging from simple steatosis to frank cirrhosis. It may well represent the oldest form of liver injury known to humankind. Evidence suggests that fermented beverages existed at least as early as the Neolithic period (circa 10,000 B.C.),5 and liver disease related to it almost as long. Alcohol remains a major cause of liver disease worldwide. It is common for patients with ALD to share risk factors for simultaneous injury from other liver insults (e.g., coexisting nonalcoholic fatty liver disease, or chronic viral hepatitis). Many of the natural history studies of ALD, and even treatment trials, were performed before these other liver diseases were recognized, or specific testing was possible. Thus, the individual effect of alcohol in some of these studies may have been confounded by the presence of these additional injuries. Despite this limitation, the data regarding ALD are robust enough to draw conclusions about the pathophysiology of this disease. Possible factors that affect the development of liver injury include the dose, duration, and type of alcohol consumption; drinking patterns; sex; ethnicity; and associated risk factors including obesity, iron overload, concomitant infection with viral hepatitis, and genetic factors. Geographic variability exists in the patterns of alcohol intake throughout the world.6 Approximately two-thirds of adult Americans drink some alcohol.7 The majority drink small or moderate amounts and do so without evidence of clinical disease.8-10 A subgroup of drinkers, however, drink excessively, develop physical tolerance and withdrawal, and are diagnosed with alcohol dependence.11 A second subset, alcohol abusers and problem drinkers, are those who engage in harmful use of alcohol, defined by the development of negative social and health consequences of drinking (e.g., unemployment, loss of family, organ damage, accidental injury, or death).12 Failure to recognize alcoholism remains a significant problem and impairs efforts at both the prevention and management of patients with ALD.13, 14 Although the exact prevalence is unknown, approximately 7.4% of adult Americans were estimated to meet DSM-IV criteria for the diagnosis of alcohol abuse and/or alcohol dependence in 199415; more recent data suggest 4.65% meet criteria for alcohol abuse and 3.81% for alcohol dependence.16 In 2003, 44% of all deaths from liver disease were attributed to alcohol.17 Population level mortality from alcoholic liver disease is related to per capita alcohol consumption obtained from national alcoholic beverage sales data. There are conflicting data regarding a possible lower risk of liver injury in wine drinkers.18, 19 One epidemiologic study has estimated that for every 1-liter increase in per capita alcohol consumption (independent of type of beverage), there was a 14% increase in cirrhosis in men and 8% increase in women.20 These data must be considered in the context of the limi
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
S-adenosyl-L-methionine for alcoholic liver diseases
Rambaldi, A., & Gluud, C. N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002235.pub2 · Cited by 134
RetractedSAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597
A Model to Predict Survival in Patients With End–Stage Liver Disease
Kamath, P. S., Wiesner, R. H., Malinchoc, M., Kremers, W., Therneau, T. M., Kosberg, C. L., D'Amico, G., Dickson, R. E., & Kim, R. W. (2001) · Hepatology · doi:10.1053/jhep.2001.22172 · Cited by 4,975
Selected major risk factors and global and regional burden of disease
Ezzati, M., Lopez, A. D., Rodgers, A., Vander Hoorn, S., & Murray, C. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11403-6 · Cited by 3,594
Detecting Alcoholism: The CAGE Questionnaire
Ewing, J. A. (1984) · JAMA · doi:10.1001/jama.1984.03350140051025 · Cited by 3,005
Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2003 · Cited by 1,930
Frezza, M., di Padova, C., Pozzato, G., Terpin, M., Baraona, E., & Lieber, C. S. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001113220205 · Cited by 1,328
Yokota, T., Oritani, K., Takahashi, I., Ishikawa, J., Matsuyama, A., Ouchi, N., Kihara, S., Funahashi, T., Tenner, A. J., Tomiyama, Y., et al. (2000) · Blood · doi:10.1182/blood.v96.5.1723 · Cited by 1,297
Li, Z., Yang, S., Lin, H., Huang, J., Watkins, P. A., Moser, A. B., DeSimone, C., Song, X.-Y., & Diehl, A. M. (2003) · Hepatology · doi:10.1053/jhep.2003.50048 · Cited by 930
Corticosteroid therapy of alcoholic hepatitis
Maddrey, W. C., Boitnott, J. K., Bedine, M. S., Weber, F. L., Mezey, E., & White, R. I. (1978) · Gastroenterology · doi:10.1016/0016-5085(78)90401-8 · Cited by 925
Cited by
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Gao, B., & Bataller, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.09.002 · Cited by 1,963
Mouse model of chronic and binge ethanol feeding (the NIAAA model)
Bertola, A., Mathews, S., Ki, S. H., Wang, H., & Gao, B. (2013) · Nature Protocols · doi:10.1038/nprot.2013.032 · Cited by 1,213
Seitz, H. K., Bataller, R., Cortez-Pinto, H., Gao, B., Gual, A., Lackner, C., Mathurin, P., Mueller, S., Szabo, G., & Tsukamoto, H. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0014-7 · Cited by 1,271
EASL Clinical Practice Guidelines: Liver transplantation
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.006 · Cited by 1,082
Martin, P., DiMartini, A., Feng, S., Brown, R., & Fallon, M. (2014) · Hepatology · doi:10.1002/hep.26972 · Cited by 1,045
Early Liver Transplantation for Severe Alcoholic Hepatitis
Mathurin, P., Moreno, C., Samuel, D., Dumortier, J., Salleron, J., Durand, F., Castel, H., Duhamel, A., Pageaux, G.-P., Leroy, V., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105703 · Cited by 960
Prednisolone or Pentoxifylline for Alcoholic Hepatitis
Thursz, M. R., Richardson, P., Allison, M., Austin, A., Bowers, M., Day, C. P., Downs, N., Gleeson, D., MacGilchrist, A., Grant, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412278 · Cited by 769
Global burden of alcoholic liver diseases
Rehm, J., Samokhvalov, A. V., & Shield, K. D. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.007 · Cited by 740
IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice
Petrasek, J., Bala, S., Csak, T., Lippai, D., Kodys, K., Menashy, V., Barrieau, M., Min, S.-Y., Kurt-Jones, E. A., & Szabo, G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60777 · Cited by 735
de Lope, C. R., Tremosini, S., Forner, A., Reig, M., & Bruix, J. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60009-9 · Cited by 610
Inflammasome activation and function in liver disease
Szabo, G., & Petrasek, J. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.94 · Cited by 597
Ferraioli, G., Wong, V. W.-S., Castera, L., Berzigotti, A., Sporea, I., Dietrich, C. F., Choi, B. I., Wilson, S. R., Kudo, M., & Barr, R. G. (2018) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2018.07.008 · Cited by 574
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors
Huang, D. Q., Mathurin, P., Cortez-Pinto, H., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00688-6 · Cited by 553
Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review
Gillessen, A., & Schmidt, H. H.-J. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01251-y · Cited by 490
Ki, S. H., Park, O., Zheng, M., Morales-Ibanez, O., Kolls, J. K., Bataller, R., & Gao, B. (2010) · Hepatology · doi:10.1002/hep.23837 · Cited by 434
Glucocorticoids plus N-Acetylcysteine in Severe Alcoholic Hepatitis
Nguyen-Khac, E., Thevenot, T., Piquet, M.-A., Benferhat, S., Goria, O., Chatelain, D., Tramier, B., Dewaele, F., Ghrib, S., Rudler, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1101214 · Cited by 410
Alcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis
Roerecke, M., Vafaei, A., Hasan, O. S. M., Chrystoja, B. R., Cruz, M., Lee, R., Neuman, M. G., & Rehm, J. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000340 · Cited by 391
Myers, R. P., Pollett, A., Kirsch, R., Pomier‐Layrargues, G., Beaton, M., Levstik, M., Duarte‐Rojo, A., Wong, D., Crotty, P., & Elkashab, M. (2012) · Liver International · doi:10.1111/j.1478-3231.2012.02781.x · Cited by 343
Momen-Heravi, F., Saha, B., Kodys, K., Catalano, D., Satishchandran, A., & Szabo, G. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0623-9 · Cited by 307
Inflammation in Alcoholic Liver Disease
Wang, H. J., Gao, B., Zakhari, S., & Nagy, L. E. (2012) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-072610-145138 · Cited by 297
Lackner, C., Spindelboeck, W., Haybaeck, J., Douschan, P., Rainer, F., Terracciano, L., Haas, J., Berghold, A., Bataller, R., & Stauber, R. E. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.11.011 · Cited by 293
Alcoholic liver disease: pathogenesis and new targets for therapy
Altamirano, J., & Bataller, R. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.134 · Cited by 284
Alcoholic Liver Disease: The Gut Microbiome and Liver Cross Talk
Hartmann, P., Seebauer, C. T., & Schnabl, B. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12704 · Cited by 282
Bertola, A., Park, O., & Gao, B. (2013) · Hepatology · doi:10.1002/hep.26419 · Cited by 282
Recent progress regarding kaempferol for the treatment of various diseases (Review)
Ren, J., Lu, Y., Qian, Y., Chen, B., Wu, T., & Ji, G. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7886 · Cited by 259
Treatment options for alcoholic and non-alcoholic fatty liver disease: A review
Singh, S., Osna, N. A., & Kharbanda, K. K. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6549 · Cited by 257
The Effect of Inflammatory Cytokines in Alcoholic Liver Disease
Kawaratani, H., Tsujimoto, T., Douhara, A., Takaya, H., Moriya, K., Namisaki, T., Noguchi, R., Yoshiji, H., Fujimoto, M., & Fukui, H. (2013) · Mediators of Inflammation · doi:10.1155/2013/495156 · Cited by 256
Im, G. Y., Kim-Schluger, L., Shenoy, A., Schubert, E., Goel, A., Friedman, S. L., Florman, S., & Schiano, T. D. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13586 · Cited by 253
Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine
De Andrade, K., Moura, F., Dos Santos, J., De Araújo, O., De Farias Santos, J., & Goulart, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226225 · Cited by 253
Summa, K. C., Voigt, R. M., Forsyth, C. B., Shaikh, M., Cavanaugh, K., Tang, Y., Vitaterna, M. H., Song, S., Turek, F. W., & Keshavarzian, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067102 · Cited by 252
Saha, B., Momen-Heravi, F., Kodys, K., & Szabo, G. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.694133 · Cited by 229
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00822-y · Cited by 207
Chen, R.-C., Xu, L.-M., Du, S.-J., Huang, S.-S., Wu, H., Dong, J.-J., Huang, J.-R., Wang, X.-D., Feng, W.-K., & Chen, Y.-P. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2015.11.019 · Cited by 123
Depression and chronic liver diseases: are there shared underlying mechanisms?
Huang, X., Liu, X., & Yu, Y. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00134 · Cited by 121
Aravinthan, A., Pietrosi, G., Hoare, M., Jupp, J., Marshall, A., Verrill, C., Davies, S., Bateman, A., Sheron, N., Allison, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072904 · Cited by 117
Alcoholic hepatitis: Translational approaches to develop targeted therapies
Mandrekar, P., Bataller, R., Tsukamoto, H., & Gao, B. (2016) · Hepatology · doi:10.1002/hep.28530 · Cited by 115
Association of chronic liver disease with depression: A population-based study
Lee, K., Otgonsuren, M., Younoszai, Z., Mir, H. M., & Younossi, Z. M. (2013) · Psychosomatics · doi:10.1016/j.psym.2012.09.005 · Cited by 104
The NLRP3 inflammasome in alcoholic and nonalcoholic steatohepatitis
Knorr, J., Wree, A., Tacke, F., & Feldstein, A. E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708540 · Cited by 99
The impact of obesity and metabolic syndrome on alcoholic liver disease
Chiang, D. J., & McCullough, A. J. (2014) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.09.006 · Cited by 99
Self-citationKietzmann, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092347 · Cited by 90
Spectrum of alcoholic liver disease
Chacko, K. R., & Reinus, J. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.02.002 · Cited by 86
c-MYC—Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease
Zheng, K., Cubero, F., & Nevzorova, Y. (2017) · Genes · doi:10.3390/genes8040123 · Cited by 84
Intestinal CYP2E1: A mediator of alcohol-induced gut leakiness
Forsyth, C. B., Voigt, R. M., & Keshavarzian, A. (2014) · Redox Biology · doi:10.1016/j.redox.2014.10.002 · Cited by 76
Roles of Macrophages and Exosomes in Liver Diseases
Shen, M., Shen, Y., Fan, X., Men, R., Ye, T., & Yang, L. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.583691 · Cited by 61
Adult mouse model of early hepatocellular carcinoma promoted by alcoholic liver disease
Ambade, A., Satishchandran, A., Gyongyosi, B., Lowe, P., & Szabo, G. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i16.4091 · Cited by 52
Pharmacotherapy for alcoholic patients with alcoholic liver disease
Vuittonet, C. L., Halse, M., Leggio, L., Fricchione, S. B., Brickley, M., Haass-Koffler, C. L., Tavares, T., Swift, R. M., & Kenna, G. A. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140028 · Cited by 51
Bone microarchitecture and bone turnover in hepatic cirrhosis
Wakolbinger, R., Muschitz, C., Scheriau, G., Bodlaj, G., Kocijan, R., Feichtinger, X., Schanda, J. E., Haschka, J., Resch, H., & Pietschmann, P. (2019) · Osteoporosis International · doi:10.1007/s00198-019-04870-6 · Cited by 39
Authors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30
Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease
Maccioni, L., Leclercq, I. A., Schnabl, B., & Stärkel, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312687 · Cited by 31
Metabolic injury of hepatocytes promotes progression of NAFLD and AALD
Carvalho-Gontijo, R., Han, C., Zhang, L., Zhang, V., Hosseini, M., Mekeel, K., Schnabl, B., Loomba, R., Karin, M., Brenner, D. A., et al. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1755316 · Cited by 23
Maccioni, L., Horsmans, Y., Leclercq, I., Schnabl, B., & Stärkel, P. (2023) · Alcohol: Clinical and Experimental Research · doi:10.1111/acer.15081 · Cited by 10
Metadata
- Authors
- O'Shea, R. S., Dasarathy, S., & McCullough, A. J.
- Venue
- Hepatology
- Published
- 2010-01
- Volume
- 51
- Issue
- 1
- Pages
- 307-328
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W4211110117
- Cited by
- 1,077
- References
- 221
- FWCI
- 19.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.